Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals (DE:H5P)
:H5P
H5P Analyst Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
H5P Stock 12 Month Forecast
Average Price Target
€30.04
▲(9.65% Upside)
| Highest Price Target€37.42 | Average Price Target€30.04 | Lowest Price Target€24.14 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Reiterated
02/12/25
Berenberg Bank
Reiterated
01/30/25
Barclays
Reiterated
12/20/24
RBC Capital
Upgraded
12/10/24
J.P. Morgan
Reiterated
12/03/24
Deutsche Bank
€33.19→€37.41
Buy
36.54%
Upside
Reiterated
11/25/24
Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Raised to GBP31 at Deutsche BankDeutsche Bank analyst Paul Cuddon raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP31.00 (from GBP27.50) while maintaining a Buy rating.
Stifel Nicolaus
€30.17
Buy
10.11%
Upside
Reiterated
11/07/24
Hikma Pharmaceuticals: Strategic Growth and Attractive Valuation Reinforce Buy Rating
Citi
€34.33
Buy
25.31%
Upside
Assigned
08/09/24
Citi Issues a Buy Rating on Hikma Pharmaceuticals (HIK)
CFRA
€26.55→€24.14
Hold
-11.91%
Downside
Reiterated
04/26/24
Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Lowered to GBP20 at CFRACFRA analyst Wan Nurhayati lowered the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP20.00 (from GBP22.00) while maintaining a Hold rating.
Best Analysts Covering Hikma
Which Analyst Should I Follow If I Want to Buy DE:H5P and Sell After:
1 Month
xxx
Success Rate
7/15 ratings generated profit
Average Return
+2.13%
assigned a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 46.67% of your transactions generating a profit, with an average return of +2.13% per trade.
3 Months
xxx
Success Rate
11/15 ratings generated profit
Average Return
+7.31%
assigned a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +7.31% per trade.
1 Year
Success Rate
12/15 ratings generated profit
Average Return
+8.15%
assigned a buy rating 7 months ago
Copying Peter Verdult's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +8.15% per trade.
2 Years
xxx
Success Rate
10/15 ratings generated profit
Average Return
+9.43%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +9.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
H5P Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
0
0
0
0
0
Buy
5
4
5
5
3
Hold
4
1
2
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
5
7
7
5
Each month's total comprises the sum of three months' worth of ratings.
H5P Financial Forecast
H5P Stock Forecast FAQ
What is DE:H5P’s average 12-month price target, according to analysts?
Based on analyst ratings, Hikma Pharmaceuticals’s 12-month average price target is €30.04.
What is DE:H5P’s upside potential, based on the analysts’ average price target?
Hikma Pharmaceuticals has 9.65% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Hikma Pharmaceuticals a Buy, Sell or Hold?
Hikma Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
What is Hikma Pharmaceuticals’s share price target?
The average share price target for Hikma Pharmaceuticals is €30.04. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €37.42 ,and the lowest forecast is €24.14. The average share price target represents 9.65% Increase from the current price of €27.4.
The highest analyst share price target is €37.42 ,and the lowest forecast is €24.14. The average share price target represents 9.65% Increase from the current price of €27.4.
What do analysts say about Hikma Pharmaceuticals?
Hikma Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
How can I buy shares of Hikma Pharmaceuticals?
To buy shares of DE:H5P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.